De to hyppigst indberettede bivirkninger i en fase IV sammenlignende klinisk undersøgelse blandt toxin- naive patienter behandlet med NeuroBloc 10. 000 E til 15. 000 E var mundtørhed og synkebesvær, som blev indberettet med en hyppighed på henholdsvis 44% og 35%.
The two most commonly reported undesirable effects in a Phase IV comparative clinical study among toxin naïve patients treated with NeuroBloc 10,000 U to 15,000 U were dry mouth and dysphagia, which were reported at a frequency of 44% and 35%, respectively.